Prime Medicine Inc. Common Stock (PRME)
Stock · NASDAQ · Health Care
$3.47as of 10/16/2026
Price chart
Active signals
PRME Signal Track Record
How signals performed across all stocks →What PRME's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 24 | -6.9% | 42% | October 6, 2026 |
| Bollinger Band Breakout | 16 | -14.1% | 38% | October 7, 2026 |
| Bollinger Band Breakdown | 15 | -9.1% | 40% | September 16, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -8.4% | 40% | October 6, 2026 |
| Any 20-session window (baseline) | -5.9% | 40% |
Computed by MarketWall from daily closing prices since August 8, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PRME
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 146
- Website
- primemedicine.com/
Fundamentals
- 1-day range
- $3.42$3.61
- Market cap
- $532.82M
- P/E (trailing)
- —
- P/E (forward)
- -3.99
- EPS (trailing)
- $-1.09
- Dividend yield
- —
- Beta
- 2.35
- Avg. volume
- 3.45M
How Prime Medicine Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 3, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
Prime Medicine Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PRMEPrime Medicine Inc. Common Stock$3.47▼ 3.88%Market cap $532.82MP/E —$2.67$6.65
- AUTLAutolus Therapeutics plc American Depositary Share$1.6▼ 6.98%Market cap $532.31MP/E —$1.18$2.58
- DNAGinkgo Bioworks Holdings Inc. Class A Common Stock$10.27▼ 12.67%Market cap $528.15MP/E —$5.37$18.22
- ZURAZura Bio Limited Class A Ordinary Shares$3.88▼ 9.35%Market cap $542.44MP/E —$3.15$7.44
- FDMT4D Molecular Therapeutics Inc. Common Stock$12.14▼ 5.67%Market cap $551.51MP/E —$6.96$16.93
- ARTVArtiva Biotherapeutics Inc. Common Stock$5.85▼ 3.47%Market cap $566.10MP/E —$2.75$14.53
- EIKNEikon Therapeutics Inc. Common Stock$7.42▼ 1.59%Market cap $498.62MP/E —$6.45$17.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PRME Prime Medicine Inc. Common Stock | $532.82M | — | $3.47 | ▼ 3.88% | $2.67$6.65 |
| AUTL Autolus Therapeutics plc American Depositary Share | $532.31M | — | $1.6 | ▼ 6.98% | $1.18$2.58 |
| DNA Ginkgo Bioworks Holdings Inc. Class A Common Stock | $528.15M | — | $10.27 | ▼ 12.67% | $5.37$18.22 |
| ZURA Zura Bio Limited Class A Ordinary Shares | $542.44M | — | $3.88 | ▼ 9.35% | $3.15$7.44 |
| FDMT 4D Molecular Therapeutics Inc. Common Stock | $551.51M | — | $12.14 | ▼ 5.67% | $6.96$16.93 |
| ARTV Artiva Biotherapeutics Inc. Common Stock | $566.10M | — | $5.85 | ▼ 3.47% | $2.75$14.53 |
| EIKN Eikon Therapeutics Inc. Common Stock | $498.62M | — | $7.42 | ▼ 1.59% | $6.45$17.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On FridayBenzinga · 10/9/2026
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga · 10/7/2026
- Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On TuesdayBenzinga · 10/6/2026
- Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson DiseaseYahoo · 10/5/2026
- Temporary Weakness in Intellia Stock Seems Like a Buying OpportunityYahoo · 9/29/2026
- Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical ProgressSeekingAlpha · 9/29/2026
- Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 AdvancementSeekingAlpha · 9/25/2026
- Prime Medicine Gets FDA Green Light for Gene Editing StudyBenzinga · 9/25/2026
- Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Fridaybenzinga · 9/25/2026
Insider Activity
Insider Actions →- Chung Wendy · June 5, 2026 · Grant75.0K
- Cahill Thomas · June 5, 2026 · Grant75.0K
- Michael Aaron Kelly · June 5, 2026 · Grant75.0K
- Marrazzo Jeffrey D · June 5, 2026 · Grant75.0K
- David P. Schenkein · June 5, 2026 · Grant75.0K
- Foster-Cheek Kaye I · June 5, 2026 · Grant75.0K
- Robert Nelsen · June 5, 2026 · Grant75.0K
- Makhni Svetlana Ni · April 16, 2026 · Grant800.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 97.04M
- Total value held
- $311.91M
- Institutional holders
- 185
- Unknown16.56M
- Unknown8.50M
- Unknown6.35M
- Unknown6.25M
- Unknown5.48M
- Unknown4.47M
- Unknown4.12M
- Unknown3.17M
- Unknown3.00M
- Unknown2.94M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Prime Medicine stock surges after FDA clears IND for PM647
Prime Medicine shares rose significantly after the U.S. FDA cleared the Investigational New Drug application for PM647, a gene editing therapy for alpha-1 antitrypsin deficiency. This regulatory approval allows the company to begin clinical trials for the treatment. The positive news for Prime Medicine occurred alongside a broader decline in gene-editing stocks triggered by recent developments involving Anthropic AI.
Prime Medicine stock surges after FDA clears IND for PM647. Prime Medicine shares rose significantly after the U.S. FDA cleared the Investigational New Drug application for PM647, a gene editing therapy for alpha-1 antitrypsin deficiency. This regulatory approval allows the company to begin clinical trials for the treatment. The positive news for Prime Medicine occurred alongside a broader decline in gene-editing stocks triggered by recent developments involving Anthropic AI.